

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Eugeni A. VAISBERG, et al.

Attorney Docket No.: CYTOP007

Application No.: 09/311,996

Examiner: John S. Briscoe

Filed: 05/14/1999

Group: 1631

Title: DATABASE SYSTEM INCLUDING
COMPUTER FOR PREDICTIVE CELLULAR
BIOINFORMATICS

RECEIVED
JUL 14 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first-class mail on July 7, 2003 in an envelope addressed to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Signed: _____

Sally Zumba

**INFORMATION DISCLOSURE STATEMENT
BEFORE FINAL ACTION OR NOTICE OF ALLOWANCE
(37 CFR §§ 1.56 AND 1.97(c))**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The references listed in the attached PTO Form 1449, a copy of which is attached, may be material to examination of the above-identified patent application. Applicants submit this reference in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make this citation of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this reference indeed constitutes prior art.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits, but it is believed before the mailing date of either: (i) a final action under §1.113 or (ii) a notice of allowance under §1.311, whichever occurs first.


Accompanying this Information Disclosure Statement is

- ☐ a statement as specified in 37 CFR 1.97(e); or
☒ the fee set forth in 37 CFR 1.17(p).

If fees are due, enclosed is our Check No. 19187 for \$180.00 in payment of the Information Disclosure Statement Fee. If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. CYTOP007).

Respectfully submitted,


BEYER WEAVER & THOMAS, LLP



Lauren L. Stevens, Ph.D.

Registration No. 36,691

P.O. Box 778
Berkeley, CA 94704-0778
(650) 961-8300
IDS before FOA3.doc



Form 1449 (Modified) Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)		Atty Docket No. CYTOP007 Applicant: Eugeni A. VAISBERG, et al. Filing Date 5/14/1999	Application No.: 09/311,996 Group 1631
----------------------------------------------------------------------------------------------------------------------------------	--	-------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
	A1	RE 34,214	4/1993	Carlsson et al.			
	A2	4,818,710	4/1989	Sutherland et al.			
	A3	4,922,092	5/1990	Rushbrooke et al.			
	A4	5,287,272	2/1994	Rutenberg et al.			
	A5	5,326,691	7/1994	Hozier			
	A6	5,355,215	10/1994	Schroeder et al.			
	A7	5,526,258	6/1996	Bacus			
	A8	5,733,721	3/1998	Hemstreet III et al.			
	A9	5,777,888	7/1998	Rine et al.			
	A10	5,893,095	4/1999	Jain et al.			
	A11	5,962,250	10/1999	Gavin et al.			
	A12	6,083,763	7/2000	Balch			
	A13	6,146,830	11/2000	Friend et al.			
	A14	6,222,093	4/2001	Marton et al.			
	A15	6,345,115	2/2002	Ramm et al.			


RECEIVED
 JUL 14 2003
 TECH CENTER 1600/2900

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
	B1	EP 0 317 139	2/11/95	EP				
	B2	WO 93/21511	28/10/93	PCT				
	B3	WO 94/11841	26.05.94	PCT				
	B4	WO 95/22749	24/08/95	PCT				
	B5	WO 96/09605	28/03/96	PCT				
	B6	WO 97/43732	20/11/97	PCT				
	B7	WO 99/05323	04/02/99	PCT				
	B8	WO 00/65472	02/11/00	PCT				
	B9	WO 00/70528	23/11/00	PCT				

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	C1	ADAMS, Terri and KAPUR, Ravi; US Provisional Appln. Serial No. 60/138,119, filed June 7, 1999



RECEIVED

JUL 14 2003

TECH CENTER 1600/2900

C2	BLANKENSTEIN, Gert et al., "Modular concept of a laboratory for chemical and biochemical analysis", 1998, Biocensors & Bioelectronics, Vol. 13, No. 3-4, pp. 427-438.
C3	CSEKE, István, "A Fast Segmentation Scheme for White Blood Cell Images", 1992, Geometry GIS System House Ltd., Budapest, pp. 530-533.
C4	HARTWELL, Leland H., et al., "Integrating Genetic Approaches into the Discovery of Anticancer Drugs", 7 November 1997, Science, Vol. 278, pp. 1064-1068.
C5	HOFLAND, Leo J., et al., "Role of Tumor-Derived Fibroblasts in the Growth of Primary Cultures of Human Breast-Cancer Cells: Effects of Epidermal Growth Factor and the Somatostatin Analogue Octreotide", 1995, Int. J. Cancer, Vol. 60, pp. 93-99.
C6	MONTIRONI, R., et al., "Computed cell cycle and DNA histogram analyses in image cytometry in breast cancer", 22 April 1993, J. Clin Pathol, Vol. 46, pp. 795-800.
C7	NG, Raymond et al., "Evaluating Multi-Dimensional Indexing Structures for Images Transformed by Principal Component Analysis", SPIE, Vol. 2670, pp. 50-60.
C8	PAUWELS, Oliver et al., "The application of computerized analysis of nuclear images and multivariate analysis to the understanding of the effects of antineoplastic agents and their mechanism of action", 1993, Meth Find Exp Clin Pharmacol, Vol. 15(2), pp. 113-124.
C9	PAUWELS, Oliver et al., "Determination of the Mechanism of Action of Anticancer Drugs by Means of the Computer-Assisted Microscope Image Analysis of Feulgen-Stained Nuclei", 1997, Journal of Pharmacological and Toxicological Methods, Vol. 37, pp. 105-115.
C10	PAUWELS, Oliver et al., "Monitoring of chemotherapy-induced morphonuclear modifications by means of digital cell-image analysis", 1993, J Cancer Res Clin Oncol, Vol. 119, pp. 533-540.
C11	PAUWELS, Oliver et al., "In Vitro Digital Cell Image Analysis of Morphonuclear Modifications Induced by Natural DNA-Interacting Anticancer Drugs in Three Neoplastic Cell Lines", 1995, Meth Find Exp Clin Pharmacol, Vol. 17(3), pp. 151-162.
C12	PAUWELS, Oliver et al., "Combination of Computerized Morphonuclear and Multivariate Analyses to Characterize In Vitro the Antineoplastic Effect of Alkylating Agents", 1995, Journal of Pharmacological and Toxicological Methods, Vol. 33, pp. 35-45.
C13	STEARNS, Mark E. et al., "Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 Stimulation of Tissue Inhibitor of Metalloproteinase-1 and Inhibition of Matrix Metalloproteinase (MMP)-2/MMP-9 Secretion", January 1999, Clinical Cancer Research, Vol. 5, pp. 189-196.
C14	TAKAYAMA, Shuichi et al., "Patterning cells and their environments using multiple laminar fluid flows in capillary networks", May 1999, Proc. Natl. Acad. Sci, Vol. 96, pp. 5545-5548.



	C15	WEINSTEIN, John N. et al., " <i>An information-intensive approach to the molecular pharmacology of cancer</i> ", 17 January 1997, Science, Vol. 275, pp. 343-349.
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
JUL 14 2003
TECH CENTER 1600/2900